Literature DB >> 23239192

Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma.

Zhang Zizhen1, Cao Hui, Shen Yanying, Shen Danping, Liu Jiahua, He Chao, Ni Xingzhi.   

Abstract

Recent studies have shown that diffuse large B-cell lymphoma (DLBCL) can be classified into germinal center B-cell-like (GCB) and non-GCB phenotypes by immunohistochemical staining. The aim of this study was to investigate the correlation of immunophenotypic classification with clinicopathological features in Chinese patients with primary gastric DLBCL to further our knowledge of this disease. Seventy-three patients with a histopathological diagnosis of primary gastric DLBCL were studied. Immunohistochemistry was carried out using the EnVision method to detect the expression of CD10, Bcl-6, and MUM1. The clinicopathologic features and follow-up data were analyzed using the Kaplan-Meier method, log-rank test, and χ (2) test. Expression of CD10 was observed in 21.9 % (16/73) of patients, Bcl-6 in 72.6 % (53/73), and MUM1 in 74.0 % (54/73). According to these data, 32.9 % (24/73) of the cases belonged to GCB subtype and 67.1 % (49/73) belonged to non-GCB subtype. There was a significant difference in tumor size and local lymph node metastasis between the GCB and non-GCB groups (P < 0.05). Complications in the GCB group (4.2 %) occurred less frequently than those in the non-GCB group (18.4 %); however, this difference was not significant (P > 0.05). Survival analysis revealed that patients in the GCB group had an increased 5-year survival rate compared to those in the non-GCB group (58.5 % vs 35.7 %, χ (2) = 3.939, P < 0.05). The 5-year survival rate of patients undergoing R-CHOP chemotherapy was significantly longer than that of patients in the CHOP group (74.7 % vs 37.5 %, χ (2) = 4.185, P < 0.05). The immunophenotype classification of primary gastric DLBCL, which is closely related to the tumor size and local lymph nodes metastasis, was found to have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239192     DOI: 10.1007/s12253-012-9585-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  22 in total

1.  First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori.

Authors:  S Timm; M Sailer; K H Fuchs; A Greiner
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

2.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

3.  Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

Authors:  Gustaaf W van Imhoff; Evert-Jan G Boerma; Bronno van der Holt; Ed Schuuring; Leo F Verdonck; Hanneke C Kluin-Nelemans; Philip M Kluin
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

4.  Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis.

Authors:  Mattias Berglund; Ulf Thunberg; Rose-Marie Amini; Majlis Book; Göran Roos; Martin Erlanson; Johan Linderoth; Michael Dictor; Mats Jerkeman; Eva Cavallin-Ståhl; Christer Sundström; Suzanne Rehn-Eriksson; Carin Backlin; Hans Hagberg; Richard Rosenquist; Gunilla Enblad
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

5.  A clinicopathologic study of gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  S Ohashi; K Segawa; S Okamura; H Urano; S Kanamori; H Ishikawa; K Hara; A Hukutomi; K Shirai; M Maeda
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

6.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Authors:  Paul N Meyer; Kai Fu; Timothy C Greiner; Lynette M Smith; Jan Delabie; Randy D Gascoyne; German Ott; Andreas Rosenwald; Rita M Braziel; Elias Campo; Julie M Vose; Georg Lenz; Louis M Staudt; Wing C Chan; Dennis D Weisenburger
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

7.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.

Authors:  J Connor; M Ashton-Key
Journal:  Histopathology       Date:  2007-11       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.